Your browser doesn't support javascript.
loading
Bevacizumab reduces neurocan content and gene expression in newborn rat retina in vitro.
Krempel, Paloma G; Matsuda, Monique; Marquezini, Mônica V; Seixas, Thayane G; Ventura, Grasiella M; Sholl-Franco, Alfred; Miguel, Nádia C O; Monteiro, Mário L R.
Afiliação
  • Krempel PG; Laboratory of investigation in Ophthalmology (LIM-33), University of São Paulo Medical School, São Paulo, Brazil.
  • Matsuda M; Laboratory of investigation in Ophthalmology (LIM-33), University of São Paulo Medical School, São Paulo, Brazil.
  • Marquezini MV; Experimental Air Pollution Laboratory, Pathology Department, University of São Paulo Medical School and Pro-Sangue Foundation, São Paulo, Brazil.
  • Seixas TG; Pharmacy College, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil.
  • Ventura GM; Program of Cell and Developmental Biology, Institute of Biomedical Sciences, UFRJ, Rio de Janeiro, Brazil.
  • Sholl-Franco A; Laboratório de Neurogênese, Programa de Neurobiologia, Instituto de Biofísica Carlos Chagas Filho, UFRJ, Rio de Janeiro, Brazil.
  • Miguel NC; Program of Cell and Developmental Biology, Institute of Biomedical Sciences, UFRJ, Rio de Janeiro, Brazil.
  • Monteiro ML; Laboratory of investigation in Ophthalmology (LIM-33), University of São Paulo Medical School, São Paulo, Brazil.
Invest Ophthalmol Vis Sci ; 55(8): 5109-15, 2014 Jul 24.
Article em En | MEDLINE | ID: mdl-25061112
PURPOSE: Extracellular matrix (ECM) and cellular membrane proteoglycans (PGs) play important roles in neural differentiation and cell adhesion. Vascular endothelial growth factor, an important signal protein in vascular and retinal neural cell development, is retained in the ECM due to its high affinity for PG. Bevacizumab, an anti-VEGF agent, has been extensively used for treating retinal diseases in adult and newborn patients, although its effect on the developing retina remains largely unknown. The purpose of this study was to investigate the effect of bevacizumab on neurocan, phosphacan, and syndecan-3 PG levels in newborn rat retina. METHODS: Retinal explants of sixty 2-day-old Lister hooded rats were obtained after eye enucleation and maintained in culture media with or without bevacizumab for 48 hours. Immunohistochemical staining was assessed against neurocan, phosphacan, and syndecan-3. Proteoglycan content was quantified based on the intensity of immunohistochemical labeling. Gene expressions were quantified by real-time reverse-transcription polymerase chain reaction. The results from the treatment and control groups were compared. RESULTS: No significant difference in the staining intensity and mRNA expression of phosphacan and syndecan-3 was observed between the groups. However, a significant decrease in neurocan content and mRNA expression was observed in bevacizumab-treated retinal explants compared with controls. CONCLUSIONS: Bevacizumab did not affect phosphacan and syndecan-3 levels but decreased neurocan content and gene expression. Therefore, it may interfere with early postnatal retinal cell differentiation. Although further studies are necessary to confirm our findings, we suggest anti-VEGF agents be used with caution in developing retinal tissue.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteoglicanas de Sulfatos de Condroitina / Retina / Inibidores da Angiogênese / Anticorpos Monoclonais Humanizados Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Invest Ophthalmol Vis Sci Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Brasil País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteoglicanas de Sulfatos de Condroitina / Retina / Inibidores da Angiogênese / Anticorpos Monoclonais Humanizados Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Invest Ophthalmol Vis Sci Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Brasil País de publicação: Estados Unidos